-
MSD Partners with Variational AI to Harness Generative AI for Drug Discovery
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian company Variational AI to leverage the latter’s generative AI-powered model for drug discovery initiatives. Through this partnership, MSD will have early access to Variational AI’s platform, which utilizes text prompts to generate novel small molecules…
-
Gan & Lee Pharmaceuticals Receives Bolivian Approval for Insulin Aspart, Expanding Access to Rapid-Acting Insulin
•
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has received marketing approval from Bolivia’s Agencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED) for its Insulin Aspart (cartridge bottle). Insulin Aspart, a rapid-acting insulin analogue, begins to take effect within 10-20 minutes of subcutaneous…
-
China’s NHC Designates 100 Areas as National Demonstration Zones for Integrated Medical and Elderly Care
•
The National Health Commission (NHC) has announced the selection of 100 counties (cities, districts), including Beijing’s Haidian district, as national demonstration areas for the integration of medical and elderly care services. Additionally, 99 institutions, including Yuecheng Senior Living, have been designated as national demonstration institutions for this integrated care model.…
-
Roche Commences Phase II Trial of Repare Therapeutics’ ATR Inhibitor, Camonsertib, in Solid Tumors
•
Swiss pharmaceutical giant Roche (SWX: ROG) has reached a significant milestone this week with the dosing of the first patient in an open-label Phase II trial using its Canadian partner Repare Therapeutics’ (NASDAQ: RPTX) ATR inhibitor, camonsertib. The trial aims to evaluate the safety and efficacy of various targeted therapies…
-
Roche’s Tecentriq in Combination with Exelixis’s Cabometyx Meets Primary Endpoint in mCRPC Phase III Study
•
Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced positive results from a Phase III study showcasing the efficacy of its anti-PD-L1 drug Tecentriq (atezolizumab) in combination with Exelixis’s (NASDAQ: EXEL) tyrosine kinase inhibitor (TKI) Cabometyx (cabozantinib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The study focused on…
-
Pfizer’s Nurtec Approved by China’s NMPA for Acute Treatment of Migraines
•
Pfizer Inc. (NYSE: PFE), a leading pharmaceutical company in the U.S., has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for Nurtec (rimegepant), indicated for the acute treatment of migraine with or without aura. Rimegepant, developed originally by Biohaven, is the first oral CGRP…
-
Novo Nordisk’s Rybelsus Approved for Type 2 Diabetes in China, Setting New Oral Treatment Standard
•
Novo Nordisk (NYSE: NVO), a major Danish pharmaceutical company, has received approval from China’s National Medical Products Administration (NMPA) for its drug Rybelsus (semaglutide) for the treatment of type 2 diabetes. The approval covers filing numbers JXSS2200016, JXSS2200017, and JXSS2200018. Rybelsus, recognized as the world’s first and currently only oral…
-
BJ Bioscience Inc. Faces Bankruptcy as Hangzhou Court Accepts Liquidation Application
•
The Hangzhou Yuhang District People’s Court has released a document indicating that BJ Bioscience Inc.’s application for bankruptcy liquidation has been accepted for review. The Hangzhou-based firm becomes the first domestic biotech company to face insolvency this year. Established in 2018, BJ Bio focused on research and development (R&D) of…
